PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Phenylephrine Hydrochloride In 0.9% Sodium Chloride patents expire, and what generic alternatives are available?
Phenylephrine Hydrochloride In 0.9% Sodium Chloride is a drug marketed by Dr Reddys Labs Sa and is included in one NDA. There is one patent protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is phenylephrine hydrochloride. There are twenty-one drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the phenylephrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Phenylephrine Hydrochloride In 0.9% Sodium Chloride
A generic version of PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE was approved as phenylephrine hydrochloride by HIKMA on December 20th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What are the global sales for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
Summary for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
US Patents and Regulatory Information for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 216830-001 | May 30, 2025 | RX | Yes | Yes | 12,564,561 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
See the table below for patents covering PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 124867 | ⤷ Start Trial | |
| World Intellectual Property Organization (WIPO) | 2022172253 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1534313 | 92923 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730 |
| 1534313 | 2015/071 | Ireland | ⤷ Start Trial | PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728 |
| 1534313 | 15C0090 | France | ⤷ Start Trial | PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch